Akelos Inc., of New York, appointed Thomas G. Heffner as a strategic adviser.

Arrakis Therapeutics Inc., of Waltham, Mass, appointed Elizabeth Radcliffe vice president of finance and strategy.

Conatus Pharmaceuticals Inc., of San Diego, appointed Kathleen D. Scott to its board.

Cytodyn Inc., of Vancouver, Washington, appointed Craig S. Eastwood chief financial officer.

Elucidata Corp., of Cambridge, Mass., appointed Richard Kibbey, Nick Pullen and Avi Ma'ayan to its scientific advisory board.

Eyepoint Pharmaceuticals Inc., of Watertown, Mass., appointed George O. Elston chief financial officer and head of corporate development.

Haima Therapeutics LLC, of Cleveland, appointed Jerrold Levy, Matthew Neal, Anirban Sen Gupta and Phillip Spinella to its scientific advisory board.

Hillstream Biopharma Inc., of Chester, N.J., appointed Kwok-Kin Wong to its scientific advisory board. 

Immune-Onc Therapeutics Inc., of Palo Alto, Calif., appointed Paul Woodard chief medical officer, An Song chief scientific officer, Zhengbin Yao to its board and Gregory Cosma to its scientific advisory board.

Inmune Bio Inc., of La Jolla, Calif., appointed Marcia Allen to its board.

Insmed Inc., of Bridgewater, N.J., appointed Clarissa Desjardins to its board.

Jupiter Orphan Therapeutics Inc., of Jupiter, Fla., appointed Rudolph Tanzi co-chair of its scientific advisory board.

Kymera Therapeutics Inc., of Cambridge, Mass., appointed Nello Mainolfi president and CEO.

Merck Research Laboratories, of Rahway, N.J., appointed Theodora Ross vice president of translational medicine for the discovery, preclinical and early development.

Merz North America Inc., of Raleigh, N.C., appointed Bob Rhatigan global CEO of Merz Aesthetics.

Ovid Therapeutics Inc., of New York, appointed Jason Tardio chief commercial officer.

Polyphor AG, of Allschwil, Switzerland, appointed Kuno Sommer chair and Andreas Wallnöfer vice chair of its board.

Prevail Therapeutics Inc., of New York, appointed Morgan Sheng to its board.

Relay Therapeutics Inc., of Cambridge, Mass., appointed Ben B. Wolf chief medical officer, Mrunal Phadnis vice president of clinical operations and Iain Martin vice president, drug metabolism and pharmacokinetics.

Rentschler Biopharma SE, of Laupheim, Germany, appointed Hemant Kumar vice president, process sciences and Lorraine Blackman head, human resources, U.S. 

Rockwell Medical Inc., of Wixom, Mich., appointed Marc Hoffman chief medical officer and Raymond Pratt chief development officer. The company also appointed Steven Fishbane, Jay Wish and Anatole Besarab to its medical advisory board.

Savara Inc., of Austin, Texas, appointed Badrul Chowdhury chief medical officer.

Sosei Group Corp., of Tokyo, appointed David Roblin, Peter Bernstein, Ed Bullmore, Richard Henderson, Paul Leeson, Keith Peters, Caetano Reis e Sousa, Darryle Schoepp, Roberto Solari, Christopher Tate and Anders Tullgren to its scientific advisory board. Roblin will serve as chair.

Valneva SE, of Saint Herblain, France, appointed Norman W. Baylor and George R. Siber to its scientific advisory board, effective Dec. 1.

Vifor Pharma AG, of St. Gallen, Switzerland, appointed Lee Heeson president international and member of the executive committee, effective Feb. 1, 2020.

Yumanity Therapeutics Inc., of Cambridge, Mass., appointed Brigitte Robertson chief medical officer.

No Comments